Special investment contract to strengthen AstraZeneca's position in Russia

22 December 2016

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) plans to sign a special investment contract with the Russian government, which should strengthen its position in the Russian market and improve the conditions of doing business in that country.

This has already been confirmed by Iskra Reich, general director of AstraZeneca in Russia, reports The Pharma Letter’s local correspondent.

According to Ms Reich, AstraZeneca expects to sign the contract in the first quarter of next year, while under its terms the company plans to localize up to 13 different drugs at its plant in Kaluga. Of these, six will be produced on a full cycle basis, while the remaining seven will be only the subject of packing and final quality control.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK